Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051395 | 0.97 | DPP3 (0.59) | DPP3DPP4 | |
| SCHEMBL30051339 | 0.96 | DPP4 (0.58) | DPP3DPP4BCHE | |
| SCHEMBL29666786 | 0.92 | DPP3 (0.59) | DPP3DPP4 | |
| SCHEMBL29966903 | 0.91 | DPP4 (0.54) | DPP3DPP4BCHE | |
| SCHEMBL30311056 | 0.90 | DPP3 (0.52) | DPP3DPP4BCHE | |
| SCHEMBL30051552 | 0.90 | DPP3 (0.56) | DPP3DPP4BCHE | |
| SCHEMBL30311085 | 0.90 | DPP4 (0.56) | DPP3DPP4BCHE | |
| SCHEMBL30051406 | 0.90 | DPP3 (0.58) | DPP3DPP4BCHE | |
| SCHEMBL29498130 | 0.88 | NTSR2 (0.57) | DPP3DPP4BCHE | |
| SCHEMBL30051392 | 0.88 | DPP3 (0.67) | DPP3DPP4BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | DPP3 25/4885DPP4 43/4885BCHE 353/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | DPP3 64/4885DPP4 73/4885BCHE 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.